Biochemia Medica:三级护理医院实验室关键风险结果通报方案的评估及其在临床决策中的应用

2019-11-03 MedSci MedSci原创

实验室关键风险结果的沟通对患者的安全至关重要,因为它能够实现早期决策。

实验室关键风险结果的沟通对患者的安全至关重要,因为它能够实现早期决策。我们的目的是:1)回顾性地评估当前的紧急风险电话通知方案在执行率、效率和接收者满意度方面的结果;2)评估它们在临床决策中的应用;3)为更好地评估通知方案提出替代工具。

本研究对某三级甲等医院常规实验室和统计实验室12个月内报告的生化危险结果通报进行了回顾审查。计算报告总数、通报时间和关键风险结果的主要级别。通过审查医疗记录来评估在临床决策中使用通知。通过在线问卷对要求通知的医生和护士进行满意度评估。

实验室检测总结果的0.1%为关键结果。通报的中位时间为3.2分钟(STAT)16.9分钟(常规)。重要结果较多的是常规分析中的葡萄糖和钾,STAT中的肌钙蛋白和钠。大多数通知没有反映在医疗记录中。总体平均满意度为4.2/5

研究结果表明,该方案是可行的。然而,也出现一些限制妨碍评估影响临床决策。后续应该提出了各种备选办法,以便进行适当和精确的评价。

原始出处:

Jose A. Delgado RodríguezMaria I. Pastor GarcíaAssessment of a laboratory critical risk result notification protocol in a tertiary care hospital and their use in clinical decision making

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1723211, encodeId=f7dc1e2321136, content=<a href='/topic/show?id=ab292269213' target=_blank style='color:#2F92EE;'>#临床决策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22692, encryptionId=ab292269213, topicName=临床决策)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=810a33379458, createdName=wwzzly, createdTime=Sat May 09 10:59:00 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918903, encodeId=f173191890381, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jan 21 10:59:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1689560, encodeId=910516895607d, content=<a href='/topic/show?id=ad0619e19b0' target=_blank style='color:#2F92EE;'>#三级#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19719, encryptionId=ad0619e19b0, topicName=三级)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eeb28833546, createdName=luckyshitiancai_42705693, createdTime=Wed Mar 11 09:59:00 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859001, encodeId=5ef5185900198, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Mar 19 10:59:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541846, encodeId=e37f1541846f3, content=<a href='/topic/show?id=e8ca3108823' target=_blank style='color:#2F92EE;'>#决策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31088, encryptionId=e8ca3108823, topicName=决策)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e76e13331157, createdName=ms2999106592497887, createdTime=Tue Nov 05 01:59:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610076, encodeId=fe7c16100e669, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Nov 05 01:59:00 CST 2019, time=2019-11-05, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1723211, encodeId=f7dc1e2321136, content=<a href='/topic/show?id=ab292269213' target=_blank style='color:#2F92EE;'>#临床决策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22692, encryptionId=ab292269213, topicName=临床决策)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=810a33379458, createdName=wwzzly, createdTime=Sat May 09 10:59:00 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918903, encodeId=f173191890381, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jan 21 10:59:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1689560, encodeId=910516895607d, content=<a href='/topic/show?id=ad0619e19b0' target=_blank style='color:#2F92EE;'>#三级#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19719, encryptionId=ad0619e19b0, topicName=三级)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eeb28833546, createdName=luckyshitiancai_42705693, createdTime=Wed Mar 11 09:59:00 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859001, encodeId=5ef5185900198, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Mar 19 10:59:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541846, encodeId=e37f1541846f3, content=<a href='/topic/show?id=e8ca3108823' target=_blank style='color:#2F92EE;'>#决策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31088, encryptionId=e8ca3108823, topicName=决策)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e76e13331157, createdName=ms2999106592497887, createdTime=Tue Nov 05 01:59:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610076, encodeId=fe7c16100e669, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Nov 05 01:59:00 CST 2019, time=2019-11-05, status=1, ipAttribution=)]
    2020-01-21 sunylz
  3. [GetPortalCommentsPageByObjectIdResponse(id=1723211, encodeId=f7dc1e2321136, content=<a href='/topic/show?id=ab292269213' target=_blank style='color:#2F92EE;'>#临床决策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22692, encryptionId=ab292269213, topicName=临床决策)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=810a33379458, createdName=wwzzly, createdTime=Sat May 09 10:59:00 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918903, encodeId=f173191890381, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jan 21 10:59:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1689560, encodeId=910516895607d, content=<a href='/topic/show?id=ad0619e19b0' target=_blank style='color:#2F92EE;'>#三级#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19719, encryptionId=ad0619e19b0, topicName=三级)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eeb28833546, createdName=luckyshitiancai_42705693, createdTime=Wed Mar 11 09:59:00 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859001, encodeId=5ef5185900198, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Mar 19 10:59:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541846, encodeId=e37f1541846f3, content=<a href='/topic/show?id=e8ca3108823' target=_blank style='color:#2F92EE;'>#决策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31088, encryptionId=e8ca3108823, topicName=决策)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e76e13331157, createdName=ms2999106592497887, createdTime=Tue Nov 05 01:59:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610076, encodeId=fe7c16100e669, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Nov 05 01:59:00 CST 2019, time=2019-11-05, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1723211, encodeId=f7dc1e2321136, content=<a href='/topic/show?id=ab292269213' target=_blank style='color:#2F92EE;'>#临床决策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22692, encryptionId=ab292269213, topicName=临床决策)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=810a33379458, createdName=wwzzly, createdTime=Sat May 09 10:59:00 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918903, encodeId=f173191890381, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jan 21 10:59:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1689560, encodeId=910516895607d, content=<a href='/topic/show?id=ad0619e19b0' target=_blank style='color:#2F92EE;'>#三级#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19719, encryptionId=ad0619e19b0, topicName=三级)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eeb28833546, createdName=luckyshitiancai_42705693, createdTime=Wed Mar 11 09:59:00 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859001, encodeId=5ef5185900198, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Mar 19 10:59:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541846, encodeId=e37f1541846f3, content=<a href='/topic/show?id=e8ca3108823' target=_blank style='color:#2F92EE;'>#决策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31088, encryptionId=e8ca3108823, topicName=决策)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e76e13331157, createdName=ms2999106592497887, createdTime=Tue Nov 05 01:59:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610076, encodeId=fe7c16100e669, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Nov 05 01:59:00 CST 2019, time=2019-11-05, status=1, ipAttribution=)]
    2020-03-19 jeanqiuqiu
  5. [GetPortalCommentsPageByObjectIdResponse(id=1723211, encodeId=f7dc1e2321136, content=<a href='/topic/show?id=ab292269213' target=_blank style='color:#2F92EE;'>#临床决策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22692, encryptionId=ab292269213, topicName=临床决策)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=810a33379458, createdName=wwzzly, createdTime=Sat May 09 10:59:00 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918903, encodeId=f173191890381, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jan 21 10:59:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1689560, encodeId=910516895607d, content=<a href='/topic/show?id=ad0619e19b0' target=_blank style='color:#2F92EE;'>#三级#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19719, encryptionId=ad0619e19b0, topicName=三级)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eeb28833546, createdName=luckyshitiancai_42705693, createdTime=Wed Mar 11 09:59:00 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859001, encodeId=5ef5185900198, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Mar 19 10:59:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541846, encodeId=e37f1541846f3, content=<a href='/topic/show?id=e8ca3108823' target=_blank style='color:#2F92EE;'>#决策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31088, encryptionId=e8ca3108823, topicName=决策)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e76e13331157, createdName=ms2999106592497887, createdTime=Tue Nov 05 01:59:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610076, encodeId=fe7c16100e669, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Nov 05 01:59:00 CST 2019, time=2019-11-05, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1723211, encodeId=f7dc1e2321136, content=<a href='/topic/show?id=ab292269213' target=_blank style='color:#2F92EE;'>#临床决策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22692, encryptionId=ab292269213, topicName=临床决策)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=810a33379458, createdName=wwzzly, createdTime=Sat May 09 10:59:00 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918903, encodeId=f173191890381, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jan 21 10:59:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1689560, encodeId=910516895607d, content=<a href='/topic/show?id=ad0619e19b0' target=_blank style='color:#2F92EE;'>#三级#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19719, encryptionId=ad0619e19b0, topicName=三级)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eeb28833546, createdName=luckyshitiancai_42705693, createdTime=Wed Mar 11 09:59:00 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859001, encodeId=5ef5185900198, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Mar 19 10:59:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541846, encodeId=e37f1541846f3, content=<a href='/topic/show?id=e8ca3108823' target=_blank style='color:#2F92EE;'>#决策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31088, encryptionId=e8ca3108823, topicName=决策)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e76e13331157, createdName=ms2999106592497887, createdTime=Tue Nov 05 01:59:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610076, encodeId=fe7c16100e669, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Nov 05 01:59:00 CST 2019, time=2019-11-05, status=1, ipAttribution=)]

相关资讯

临床决策支持 (CDS) 工具:减少诊断错误,改善患者安全

诊断错误是个普遍存在而且潜在致命的问题。曾刊登于纽约时报的文章——《寻求其他观点,问问电脑如何?》强调了利用一些重要的潜在健康信息技术来减轻与错误诊断有关的伤害。人们目前也已研发出几种工具,加上计算科学的持续发展,最终将产生能超越人类最佳认知技能的方法。 想实现这个愿景,还面临着重大的难题。目前,一些可辅助进行鉴别诊断(differential diagnosis)的商业工具尚未证明能有效

Eur Radiol:肱骨外上髁炎是保守治疗还是手术治疗呢?

肱骨外上髁炎在临床上十分多见,为骨科门诊就诊率最高的常见病之一。打网球者经常反手挥拍击球,若不得法常引发本病,因此俗称为网球肘(tennis elbow)。本研究评价了MR影像学表现及临床病史对肱骨外上髁炎的临床管理的影响,通过评价进行保守治疗或手术治疗的肱骨外上髁炎患者的影像学表现及临床特点。并将结果发表在Eur Radiol上。

李博:循证是一种临床决策思维模式

认识李博,是源于参加他的循证读书会,也正是因为参加读书会,我提前看了很多关于他的内容以及他写的书,发现一个很有意思的地方:他对循证医学的执着已经延伸到生活中的各个方面,因为他有时候可以为一次聚会选地点而做出一份大众点评的评价表格。在安静的书店,第一眼见到他的时候感觉他很亲和,并不是那种一板一眼的人,但随着大家热烈的讨论才发现,他是个极度认真的人,为了搜索医学文献和做系统评价,可以打200多个电话;

PNAS:打游戏降低误诊率?科学证明有道理!

前两天,《美国科学院杂志》(PNAS)发了一篇文章,称让医生打游戏能提高医生的临床决策能力,大大降低急诊外伤患者死亡率。同时他们发现,这种形式比理论学习的效果要好得多,而单纯的理论学习和没学习没区别。

CCLM:“发送和持有”临床决策支持规则的改进,以减少不必要的维生素A,E,K,B1,B2,B3,B6和C测试

本研究在大型卫生部门的所有门诊患者中评估了维生素A,E,K,B1,B2,B3,B6和C的电子请求系统中几种“发送和保持”临床决策支持规则(CDSR)的影响。 当通过电子请求命令时,提供者(除了作为非干预对照组的所有初级保健医生之外)被要求回答关于主要适应症,症状学,疑似诊断,维生素活性剂治疗等的几个强制性问题,同时,每个维生素测试使用一个下拉列表格式。样本到达后,实验室信息系统(LIS)在内